Ryan Morgan, DO
Internal Medicine · Oklahoma City, OKNPI 1033454616
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $148,218 of the $235,002 with a category attached, or 63.1%. Kedplasma LLC accounts for 61.7% of it on its own, with 25 other manufacturers making up the rest. 2025 is the largest year on record at $110,578, more than ten times the $125 reported in 2019. Among internal medicine clinicians in OK with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 353 payments — averaging $665.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Kedplasma LLC$145K
- Lilly USA, LLC$67K
- Rhythm Pharmaceuticals, Inc.$12K
- Novo Nordisk$4K
- Madrigal Pharmaceuticals$2K
- Boehringer Ingelheim International GmbH$2K
- plus $4K from 20 others
Across 140 payments — averaging $3870.30 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Boehringer Ingelheim$239K
- AbbVie$152K
- Rhythm Pharmaceuticals, Inc.$138K
- Boehringer Ingelheim International GmbH$14K
What the payments were for
- Consulting fees$148,21863%
- Speaking & faculty fees$76,74033%
- Travel & lodging$4,2272%
- Food & beverage$5,7252%
- Education$930%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Kedplasma LLC | 45 | $145,000 |
| Lilly USA, LLC | 129 | $66,952 |
| Rhythm Pharmaceuticals, Inc. | 27 | $11,892 |
| Novo Nordisk | 45 | $3,841 |
| Madrigal Pharmaceuticals | 12 | $2,170 |
| Boehringer Ingelheim International GmbH | 11 | $1,553 |
| AbbVie(2 entities) | 27 | $1,172 |
| Amgen | 22 | $777 |
| Novartis | 7 | $220 |
| Echosens North America, Inc. | 2 | $177 |
| Dexcom, Inc. | 2 | $173 |
| Boehringer Ingelheim | 3 | $169 |
| Esperion Therapeutics, Inc. | 3 | $153 |
| Regeneron Healthcare Solutions, Inc. | 2 | $130 |
| Sanofi-aventis U.S. LLC | 1 | $125 |
| Medicure Pharma Inc. | 1 | $122 |
| Althera Pharmaceuticals LLC | 1 | $105 |
| Corcept Therapeutics | 4 | $88 |
| Reshape Lifesciences Inc. | 1 | $47 |
| Bayer | 2 | $42 |
| AstraZeneca | 1 | $22 |
| Ionis Pharmaceuticals, Inc. | 1 | $16 |
| Pfizer | 1 | $16 |
| Axsome Therapeutics, Inc. | 1 | $15 |
| Astellas Pharma US Inc | 1 | $13 |
| Currax Pharmaceuticals LLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$235,002 in reported general payments places this provider in the 95th percentile of 840 internal medicine providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 143 | $203,128 |
| OzempicSemaglutide | 94 | $135,093 |
| JardianceEmpagliflozin | 71 | $69,008 |
| WegovySemaglutide | 24 | $31,970 |
| LinzessLinaclotide | 25 | $20,662 |
| Repatha SureclickEvolocumab | 24 | $18,016 |
| EliquisApixaban | 55 | $15,917 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 18 | $10,823 |
| Repatha SyringeEvolocumab | 14 | $9,223 |
| MyrbetriqMirabegron | 11 | $8,305 |
| VascepaIcosapent Ethyl | 14 | $7,277 |
| Bromocriptine Mesylate | 24 | $5,065 |
| Imipenem-Cilastatin SodiumImipenem/Cilastatin Sodium | 14 | $2,543 |
| Naltrexone Hcl | 27 | $2,259 |
| Ezetimibe | 57 | $1,751 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro | $66,952 | $203,128143 claims |
| Novo NordiskOzempic, Wegovy | $3,841 | $167,063118 claims |
| Boehringer IngelheimJardiance, Synjardy Xr | $169 | $79,83089 claims |
| AbbVieLinzess | $1,172 | $20,66225 claims |
| PfizerEliquis | $16 | $15,91755 claims |
| Astellas Pharma US IncMyrbetriq | $13 | $8,30511 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 840 internal medicine providers in Oklahoma.
Other internal medicine in Oklahoma City
- Ali JafryOklahoma City$33K
- Samid FarooquiOklahoma City$20K
- Dale BratzlerOklahoma City$17K
- Karen ChopraOklahoma City$16K
- Charlsie RecordOklahoma City$14K
- Jeannette KelleyOklahoma City$14K
- Zain Ul Abideen AsadOklahoma City$14K
- Stuart SchraderOklahoma City$12K
- Patrick GarrisonOklahoma City$10K
- Alisha SolomonOklahoma City$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.